Astellas Pharma Europe Ltd.
www.astellas.eu
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Astellas Pharma Europe Ltd.
EMA Thumbs Up For Idorsia’s Insomnia Drug And Immunocore’s Uveal Melanoma Treatment
An insomnia drug to improve daytime functioning, a treatment for a rare type of eye cancer, and an oral migraine drug for both acute and preventive treatment are among 13 new products recommended for pan-EU approval.
Novel Sickle Cell Treatment Among 13 New Drugs On Track For EU Approval
A first-of-its-kind drug for uterine fibroids and a new monoclonal antibody treatment for COVID-19 are among several new drugs recommended for pan-EU approval this month.
Diurnal Renames Orphan Drug As Efmody, Expecting EU-Wide Approval
New treatments for congenital adrenal hyperplasia and relapsing forms of multiple sclerosis are among five drugs recommended for pan-EU approval this month. In addition, harmonized EU advice has been issued for Celltrion’s monoclonal antibody COVID-19 treatment.
Seagen Debuts In EU With Tukysa Launch & Sees UK As 'Key' Future Market
Tuomo Pätsi of US biotech firm Seagen discusses plans for the rollout of Tukysa in Europe, how it successfully used a new mechanism for approval in Great Britain, and why the UK will be a go-to market for future innovative drug filings.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice